Bruker (BRKR) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 03, 2014
Document and Entity Information	'	'
Entity Registrant Name	'BRUKER CORP	'
Entity Central Index Key	'0001109354	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	168,483,639
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$329.20	$438.70
Short-term investments	113.1	'
Accounts receivable, net	268.9	307.6
Inventories	566.8	589.8
Other current assets	121.7	95.8
Total current assets	1,399.70	1,431.90
Property, plant and equipment, net	265	299.5
Intangibles, net and other long-term assets	245.9	256.9
Total assets	1,910.60	1,988.30
Current liabilities:	'	'
Current portion of long-term debt	0.7	0.7
Accounts payable	98.5	74.8
Customer advances	210	258.6
Other current liabilities	300.8	314.5
Total current liabilities	610	648.6
Long-term debt	354.5	354.3
Other long-term liabilities	133	135.2
Commitments and contingencies (Note 10)	'	'
Shareholders' equity:	'	'
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	'	'
Common stock, $0.01 par value 260,000,000 shares authorized, 168,538,443 and 167,619,039 shares issued and 168,483,039 and 167,579,204 shares outstanding at September 30, 2014 and December 31, 2013, respectively	1.7	1.7
Treasury stock, at cost, 55,404 and 39,835 shares at September 30, 2014 and December 31, 2013, respectively	-0.9	-0.6
Accumulated other comprehensive income	98.7	182.4
Other shareholders' equity	708	662.6
Total shareholders' equity attributable to Bruker Corporation	807.5	846.1
Noncontrolling interest in consolidated subsidiaries	5.6	4.1
Total shareholders' equity	813.1	850.2
Total liabilities and shareholders' equity	$1,910.60	$1,988.30

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	260,000,000	260,000,000
Common stock, shares issued	168,538,443	167,619,039
Common stock, shares outstanding	168,483,039	167,579,204
Treasury stock, shares	55,404	39,835

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME	'	'	'	'
Product revenue	$362.20	$385	$1,127.20	$1,119.90
Service revenue	56	53.1	170.7	159.3
Other revenue	1.6	0.9	3	8.1
Total revenue	419.8	439	1,300.90	1,287.30
Cost of product revenue	214.6	208.6	638.9	610.9
Cost of service revenue	37.9	37.2	114.5	107.1
Total cost of revenue	252.5	245.8	753.4	718
Gross profit	167.3	193.2	547.5	569.3
Operating expenses:	'	'	'	'
Selling, general and administrative	108	105.7	332.5	319.6
Research and development	42.1	45.5	132.6	141.4
Other charges	12.3	10.5	21.5	21.1
Total operating expenses	162.4	161.7	486.6	482.1
Operating income	4.9	31.5	60.9	87.2
Interest and other income (expense), net	4.1	-4.7	-3.1	-16.4
Income before income taxes and noncontrolling interest in consolidated subsidiaries	9	26.8	57.8	70.8
Income tax provision	2.7	9.9	24.7	24.9
Consolidated net income	6.3	16.9	33.1	45.9
Net income attributable to noncontrolling interest in consolidated subsidiaries	0.8	0.3	2.5	1
Net income attributable to Bruker Corporation	5.5	16.6	30.6	44.9
Net income per common share attributable to Bruker Corporation shareholders:	'	'	'	'
Basic and diluted (in dollars per share)	$0.03	$0.10	$0.18	$0.27
Weighted average common shares outstanding:	'	'	'	'
Basic (in shares)	168	167	167.5	166.6
Diluted (in shares)	169.6	168.7	169.5	168.4
Comprehensive income (loss)	-76.7	53.5	-50.3	58.9
Less: Comprehensive income (loss) attributable to noncontrolling interests	0.8	0.3	2.5	1
Comprehensive income (loss) attributable to Bruker Corporation	($77.50)	$53.20	($52.80)	$57.90

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Consolidated net income	$33.10	$45.90
Adjustments to reconcile consolidated net income to cash flows from operating activities:	'	'
Depreciation and amortization	47.6	45.4
Write-down of demonstration inventories to net realizable value	22.6	24
Stock-based compensation expense	7.1	4.8
Deferred income taxes	'	-8.1
Gain on disposal of product line	-9	-0.9
Other non-cash expenses, net	11.1	1.2
Changes in operating assets and liabilities, net of acquisitions and divestitures:	'	'
Accounts receivable	21.5	-9.7
Inventories	-46.9	-34.9
Accounts payable and accrued expenses	24.7	5.7
Income taxes payable, net	-14.8	-27.6
Deferred revenue	2.2	1.3
Customer advances	-35.1	-18.9
Other changes in operating assets and liabilities, net	-19.1	-14.6
Net cash provided by operating activities	45	13.6
Cash flows from investing activities:	'	'
Purchases of short-term investments	-120.8	'
Cash paid for acquisitions, net of cash acquired	-3.9	-11.6
Proceeds from disposal of product line	12.8	0.5
Purchases of property, plant and equipment	-26.7	-41.3
Proceeds from sales of property, plant and equipment	2.9	0.8
Net cash used in investing activities	-135.7	-51.6
Cash flows from financing activities:	'	'
Proceeds from revolving lines of credit	'	19.5
Repayment of other debt, net	-0.7	-0.8
Proceeds from issuance of common stock, net	7.3	8
Changes in restricted cash	0.7	-1.3
Cash payments to noncontrolling interests	-1.1	-0.6
Net cash provided by financing activities	6.2	24.8
Effect of exchange rate changes on cash and cash equivalents	-25	9.4
Net change in cash and cash equivalents	-109.5	-3.8
Cash and cash equivalents at beginning of period	438.7	310.6
Cash and cash equivalents at end of period	$329.20	$306.80

Description_of_Business

Description of Business	9 Months Ended
	Sep. 30, 2014
Description of Business	'
Description of Business	'
	1.Description of Business
	Bruker Corporation, together with its consolidated subsidiaries (‘‘Bruker’’ or the ‘‘Company’’), is a designer, manufacturer and distributor of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications.
	The Company has two reporting segments, Bruker Scientific Instruments (BSI), which represents approximately 92% of the Company’s revenues during the nine months ended September 30, 2014, and Bruker Energy & Supercon Technologies (BEST), which represents the remainder of the Company’s revenues.  Within BSI, the Company is organized into three operating segments: the Bruker BioSpin Group, the Bruker CALID Group and the Bruker MAT Group. For financial reporting purposes, the Bruker BioSpin, Bruker CALID and Bruker MAT operating segments are aggregated into the BSI reporting segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments.
	Bruker BioSpin- Bruker BioSpin designs, manufactures and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. Bruker BioSpin’s Magnetic Resonance division sells various systems utilizing magnetic resonance technology, including magnetic resonance imaging (MRI) systems, nuclear magnetic resonance systems (NMR), and electron paramagnetic resonance systems (EPR), as well as OEM MRI magnets sold to medical device manufacturers. Bruker BioSpin’s Preclinical Imaging division sells single and multiple modality systems using MRI, position emission tomography (PET), single photon emission tomography (SPECT), computed tomography (CT), magnetic particle imaging (MPI) and optical imaging (fluorescence and bioluminescence) technologies to preclinical markets.
	Bruker CALID (Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection)- Bruker CALID designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection products.  Bruker CALID also designs, manufactures and distributes instruments based on Raman molecular spectroscopy technologies. Bruker CALID’s mass spectrometry units are typically used in applications of expression proteomics, clinical proteomics, metabolic and peptide biomarker profiling, drug discovery and development, molecular diagnostics research, molecular and systems biology, basic molecular medicine research and clinical microbiology (for research use only outside the European Union).
	Bruker MAT (Materials)- Bruker MAT designs, manufactures and distributes spectroscopy and microscopy instruments for the understanding of composition and structure in material science and life science samples.  The instruments are based on advanced technologies in X-ray fluorescence spectroscopy (XRF), X-ray diffraction (XRD), X-ray micro computed tomography (μCT), atomic force microscopy (AFM), stylus and optical metrology (SOM) and fluorescence microscopy (FM), and also include analytical tools for electron microscopes, handheld, portable, and mobile X-ray fluorescence, and spark optical emission spectroscopy systems.
	The Company’s BEST reporting segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and ‘‘big science’’ research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications, and ceramic high temperature superconductors primarily for energy grid and magnet applications.
	The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of September 30, 2014 and December 31, 2013 and for the three and nine months ended September 30, 2014 and 2013, have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year. Certain prior year amounts have been reclassified to conform to the current year presentation and had no effect on previously reported net income or cash flows.
	At September 30, 2014, the Company’s significant accounting policies and estimates, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, have not changed.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Stock-Based Compensation	'
Stock-Based Compensation	'
	2.Stock-Based Compensation
	The Company’s awards of stock-based compensation are in the form of stock options and restricted stock. The Company recorded stock-based compensation expense as follows (in millions):
			Three Months Ended September 30,						Nine Months Ended September 30,
			2014			2013			2014			2013
	Stock options		$	1.7		$	1.3		$	4.7		$	3.9
	Restricted stock		0.4			0.3			2.4			0.9
	Total stock-based compensation		$	2.1		$	1.6		$	7.1		$	4.8
	Stock-based compensation expense is amortized on a straight-line basis over the underlying vesting terms of the stock-based award. Stock options to purchase the Company’s common stock are periodically awarded to executive officers and other employees of the Company subject to a vesting period of three to five years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions regarding volatility, expected life, dividend yield and risk-free interest rates are required for the Black-Scholes model and are presented in the table below:
			2014		2013
	Risk-free interest rates		1.81%-2.10%		1.07%-2.45%
	Expected life		6.0-6.25 years		6.5 years
	Volatility		53.24%-56.24%		54.9%
	Expected dividend yield		0.0%		0.0%
	Bruker Corporation Stock Plan
	In May 2010, the Bruker Corporation 2010 Incentive Compensation Plan (the “2010 Plan”) was approved by the Company’s stockholders. The 2010 Plan provides for the issuance of up to 8,000,000 shares of the Company’s common stock. The 2010 Plan allows a committee of the Board of Directors (the “Committee”) to grant incentive stock options, non-qualified stock options and restricted stock awards. The Committee has the authority to determine which employees will receive the awards, the amount of the awards and other terms and conditions of any awards. Awards granted by the Committee typically vest over a period of three to five years.
	Stock option activity for the nine months ended September 30, 2014 was as follows:
			Shares		Weighted			Weighted		Aggregate
			Subject to		Average			Average		Intrinsic Value
			Options		Option Price			Remaining		(in millions) (b)
								Contractual
								Term (Yrs)
	Outstanding at December 31, 2013		4,877,564		$	13.12
	Granted		990,670		20.7
	Exercised		(807,275	)	9.47
	Forfeited		(181,220	)	19.29
	Outstanding at September 30, 2014		4,879,739		$	15.2		6.7		$	19.5
	Exercisable at September 30, 2014		2,496,016		$	12.23		4.9		$	16
	Exercisable and expected to vest at September 30, 2014 (a)		4,758,169		$	15.12		6.6		$	19.3
		(a)		In addition to the options that are vested at September 30, 2014, the Company expects a portion of the unvested options to vest in the future. Options expected to vest in the future are determined by applying an estimated forfeiture rate to the options that are unvested as of September 30, 2014.
		(b)		The aggregate intrinsic value is based on the positive difference between the fair value of the Company’s common stock price of $18.52 on September 30, 2014, or the date of exercises, as appropriate, and the exercise price of the underlying stock options.
	Restricted stock activity for the nine months ended September 30, 2014 was as follows:
			Shares		Weighted
			Subject to		Average Grant
			Restriction		Date Fair
					Value
	Outstanding at December 31, 2013		357,948		$	16.65
	Granted		112,129		20.68
	Vested		(160,352	)	18.41
	Outstanding at September 30, 2014		309,725		$	17.2
	At September 30, 2014, the Company expects to recognize pre-tax stock-based compensation expense of $20.8 million associated with outstanding stock option awards granted under the Company’s stock plans over the weighted average remaining service period of 2.5 years. In addition, the Company expects to recognize additional pre-tax stock-based compensation expense of $5.0 million associated with outstanding restricted stock awards granted under the Company’s stock plans over the weighted average remaining service period of 3.2 years.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share	'
Earnings Per Share	'
	3.Earnings Per Share
	Net income per common share attributable to Bruker Corporation shareholders is calculated by dividing net income attributable to Bruker Corporation by the weighted-average shares outstanding during the period. The diluted net income per share computation includes the effect of shares which would be issuable upon the exercise of outstanding stock options and the vesting of restricted stock, reduced by the number of shares which are assumed to be purchased by the Company under the treasury stock method.
	The following table sets forth the computation of basic and diluted average shares outstanding (in millions, except per share amounts):
		Three Months Ended Sept 30,				Nine Months Ended Sept 30,
		2014		2013		2014		2013
	Net income attributable to Bruker Corporation, as reported	$	5.5	$	16.6	$	30.6	$	44.9
	Weighted average shares outstanding:
	Weighted average shares outstanding-basic	168.0		167.0		167.5		166.6
	Effect of dilutive securities:
	Stock options and restricted stock	1.6		1.7		2.0		1.8
		169.6		168.7		169.5		168.4
	Net income per common share attributable to Bruker Corporation shareholders:
	Basic and diluted	$	0.03	$	0.10	$	0.18	$	0.27
	Stock options to purchase approximately 0.2 million shares and 0.7 million shares were excluded from the computation of diluted earnings per share in the three months ended September 30, 2014 and 2013, respectively, as their effect would have been anti-dilutive.  Approximately 0.2 million shares and 0.9 million shares were excluded from the computation of diluted earnings per share in the nine months ended September 30, 2014 and 2013, respectively.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value of Financial Instruments	'
Fair Value of Financial Instruments	'
	4.Fair Value of Financial Instruments
	The Company applies the following hierarchy to determine the fair value of financial instruments, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The levels in the hierarchy are defined as follows:
	Level 1:  Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
	Level 2:  Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	Level 3:  Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The valuation techniques that may be used by the Company to determine the fair value of Level 2 and Level 3 financial instruments are the market approach, the income approach and the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value based on current market expectations about those future amounts, including present value techniques, option-pricing models and the excess earnings method. The cost approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost).
	The following tables set forth the Company’s financial instruments that are measured at fair value on a recurring basis and presents them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement at September 30, 2014 and December 31, 2013 (in millions):
	September 30, 2014	Total			Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets		Observable		Inputs
					Available		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets:
	Cash equivalents	$	114.8		$	114.8	$	—	$	—
	Short-term investments	113.1			113.1		—		—
	Restricted cash	1.8			1.8		—		—
	Embedded derivatives in purchase and delivery contracts	0.3			—		0.3		—
	Long-term restricted cash	3.8			3.8		—		—
	Total assets recorded at fair value	$	233.8		$	233.5	$	0.3	$	—
	Liabilities:
	Contingent consideration	$	15.8		$	—	$	—	$	15.8
	Foreign exchange contracts	7.2			—		7.2		—
	Embedded derivatives in purchase and delivery contracts	0.3			—		0.3		—
	Fixed price commodity contracts	0.1			—		0.1		—
	Total liabilities recorded at fair value	$	23.4		$	—	$	7.6	$	15.8
	December 31, 2013	Total			Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets		Observable		Inputs
					Available		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets:
	Cash equivalents	$	6.8		$	6.8	$	—	$	—
	Restricted cash	2.7			2.7		—		—
	Foreign exchange contracts	2.3			—		2.3		—
	Embedded derivatives in purchase and delivery contracts	0.2			—		0.2		—
	Fixed price commodity contracts	0.1			—		0.1		—
	Long-term restricted cash	4.0			4.0		—		—
	Total assets recorded at fair value	$	16.1		$	13.5	$	2.6	$	—
	Liabilities:
	Contingent consideration	$	7.0		$	—	$	—	$	7.0
	Embedded derivatives in purchase and delivery contracts	0.4			—		0.4		—
	Total liabilities recorded at fair value	$	7.4		$	—	$	0.4	$	7.0
	The Company’s financial instruments consist primarily of cash equivalents, short-term investments, restricted cash, derivative instruments consisting of forward foreign exchange contracts, commodity contracts, derivatives embedded in certain purchase and sale contracts, accounts receivable, short-term borrowings, accounts payable, contingent consideration and long-term debt. The carrying amounts of the Company’s cash equivalents and restricted cash, accounts receivable, short-term borrowings and accounts payable approximate fair value due to their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The Company’s long-term debt consists principally of a private placement arrangement entered into in 2012 with various fixed interest rates based on the maturity date.  The fair value of the long-term fixed interest rate debt, which has been classified as Level 2, was $249.3 million and $244.1 million at September 30, 2014 and December 31, 2013, respectively, based on market and observable sources with similar maturity dates.
	Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities, and did not elect the fair value option for any financial assets or liabilities, which originated during the three or nine months ended September 30, 2014.
	As part of certain acquisitions, including one during the three months ended September 30, 2014, the Company recorded contingent consideration liabilities that have been classified as Level 3 in the fair value hierarchy.  The contingent consideration represents the estimated fair value of future payments to the former shareholders of applicable acquired companies based on achieving annual revenue targets and specific milestones in certain years as specified in the purchase and sale agreements.  The Company initially valued the contingent consideration using the discounted cash flow method. Total contingent consideration liabilities were $15.8 million as of September 30, 2014 and $7.0 million as of December 31, 2013. There were no changes to the fair value of the contingent consideration recognized in earnings for the three months ended September 30, 2014, and $0.1 million was recorded to Other Charges in the condensed consolidated statement of income and comprehensive income for the nine months ended September 30, 2014. The following table sets forth the changes in contingent consideration liabilities for the nine months ended September 30, 2014 (in millions):
	Balance at December 31, 2013	$	7
	Current period additions	9.2
	Current period adjustments	0.1
	Current period settlements	(0.5		)
	Balance at September 30, 2014	$	15.8
	During the second quarter of 2014, the Company commenced a program to enter into time deposits with varying maturity dates ranging from one to six months, as well as call deposits for which the Company has the ability to redeem the invested amounts over a period of 31 to 95 days.  The Company has classified these investments within cash and cash equivalents or short-term investments within the condensed consolidated balance sheet based on the call and maturity dates.
	Short-term investments are classified as available-for-sale and are reported at fair value, with unrealized gains (losses) excluded from earnings and reported, net of tax, in accumulated other comprehensive income within the accompanying condensed consolidated balance sheet. There were no unrealized gains (losses) recorded during the three and nine months ended September 30, 2014. On a quarterly basis, the Company reviews its short-term investments to determine if there have been any events that could create an impairment.  None were noted for the three and nine months ended September 30, 2014.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventories	'
Inventories	'
	5.Inventories
	Inventories consisted of the following (in millions):
		September 30,		December 31,
		2014		2013
	Raw materials	$	172.5	$	189.7
	Work-in-process	199.2		196.5
	Finished goods	149.2		155.3
	Demonstration units	45.9		48.3
	Inventories	$	566.8	$	589.8
	Finished goods include in-transit systems that have been shipped to the Company’s customers, but not yet installed and accepted by the customer. As of September 30, 2014 and December 31, 2013, inventory-in-transit was $78.8 million and $81.9 million, respectively.
	The Company reduces the carrying value of its demonstration inventories for differences between its cost and estimated net realizable value through a charge to cost of product revenue that is based on a number of factors, including the age of the unit, the physical condition of the unit and an assessment of technological obsolescence. Amounts recorded in cost of product revenue related to the write-down of demonstration units to net realizable value were $7.4 million and $8.0 million for the three months ended September 30, 2014 and 2013, respectively, and $22.6 million and $24.0 million for the nine months ended September 30, 2014 and 2013, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Other Intangible Assets	'
Goodwill and Other Intangible Assets	'
	6.Goodwill and Other Intangible Assets
	The following table sets forth the changes in the carrying amount of goodwill for the nine months ended September 30, 2014 (in millions):
	Balance at December 31, 2013	$	127.4
	Current period additions	11
	Current period adjustments	(0.1		)
	Foreign currency effect	(3.2		)
	Balance at September 30, 2014	$	135.1
	In July 2014, the Company’s Board of Directors approved a plan (the “Plan”) to divest certain assets and implement a restructuring program in the CAM division within the Bruker CALID Group. The Plan was developed as a result of management’s conclusion that the CAM business would be unable to achieve acceptable financial performance in the next two years.  Please see Note 13 — Other Charges, net, for more details on the Plan. The Company determined the Plan was an indicator requiring the evaluation of the definite-lived intangible assets within that reporting unit for recoverability. The Company had no remaining goodwill or indefinite-lived intangible assets attributable to the CAM division prior to approval of the Plan. The Company performed a valuation during the three months ended September 30, 2014 and determined that the definite-lived intangible assets within the CAM division were impaired. The Company recorded an impairment charge of $1.4 million in the three and nine months ended September 30, 2014 to write-off the remaining carrying value of those assets. This impairment charge is included as a component of Other Charges, net in the condensed consolidated statement of income and comprehensive income.
	The following is a summary of intangible assets (in millions):
		September 30, 2014								December 31, 2013
		Gross			Accumulated			Net Carrying		Gross		Accumulated			Net Carrying
		Carrying			Amortization			Amount		Carrying		Amortization			Amount
		Amount								Amount
	Existing technology and related patents	$	151.2		$	(76.7	)	$	74.5	$	157.9	$	(68.2	)	$	89.7
	Customer relationships	13.7			(5.3		)	8.4		18		(7.8		)	10.2
	Trade names	0.1			(0.1		)	—		0.2		(0.2		)	—
	Intangible assets subject to amortization	165			(82.1		)	82.9		176.1		(76.2		)	99.9
	In-process research and development	5.7			—			5.7		5.7		—			5.7
	Intangible assets	$	170.7		$	(82.1	)	$	88.6	$	181.8	$	(76.2	)	$	105.6
	For each of the three months ended September 30, 2014 and 2013, the Company recorded amortization expense of $5.1 million related to intangible assets subject to amortization.  For the nine months ended September 30, 2014 and 2013, the Company recorded amortization expense of $15.1 million and $15.3 million, respectively, related to intangible assets subject to amortization.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt	'
Debt	'
	7.Debt
	The Company’s debt obligations as of September 30, 2014 and December 31, 2013 consisted of the following (in millions):
			September 30,			December 31,
			2014			2013
	US Dollar revolving loan under the Amended Credit Agreement		$	112.5		$	112.5
	US Dollar notes under the Note Purchase Agreement		240			240
	Capital lease obligations and other loans		2.7			2.5
	Total debt		355.2			355
	Current portion of long-term debt		(0.7		)	(0.7		)
	Total long-term debt, less current portion		$	354.5		$	354.3
	In May 2011, the Company entered into an amendment to, and restatement of, its credit agreement, referred to as the Amended Credit Agreement. The Amended Credit Agreement provides a maximum commitment on the Company’s revolving credit line of $250.0 million and a maturity date of May 2016. Borrowings under the revolving credit line of the Amended Credit Agreement accrue interest, at the Company’s option, at either (a) the greatest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) adjusted LIBOR plus 1.00% or (b) LIBOR, plus margins ranging from 0.80% to 1.65%. There is also a facility fee ranging from 0.20% to 0.35%.
	Borrowings under the Amended Credit Agreement are secured by guarantees from certain material subsidiaries, as defined in the Amended Credit Agreement, and Bruker Energy & Supercon Technologies, Inc. The Amended Credit Agreement also requires the Company to maintain certain financial ratios related to maximum leverage and minimum interest coverage. Specifically, the Company’s leverage ratio cannot exceed 3.0 and the Company’s interest coverage ratio cannot be less than 3.0. As of September 30, 2014, the Company was in compliance with the covenants of the Amended Credit Agreement. In addition to the financial ratios, the Amended Credit Agreement restricts, among other things, the Company’s ability to do the following: make certain payments; incur additional debt; incur certain liens; make certain investments, including derivative agreements; merge, consolidate, sell or transfer all or substantially all of its assets; and enter into certain transactions with affiliates. Failure to comply with any of these restrictions or covenants may result in an event of default under the Amended Credit Agreement, which could permit acceleration of the debt and require the Company to prepay the debt before its scheduled due date.
	The following is a summary of the maximum commitments and net amounts available to the Company under revolving loans and lines of credit as of September 30, 2014 (in millions):
			Weighted		Total Amount			Outstanding		Outstanding		Total Amount
			Average		Committed by			Borrowings		Letters of		Available
			Interest Rate		Lenders					Credit
	Amended Credit Agreement		1.3	%	$	250.0		$	112.5	$	7.4	$	130.1
	Other revolving loans		—		260.3			—		138.3		122.0
	Total revolving loans				$	510.3		$	112.5	$	145.7	$	252.1
	Other revolving lines of credit are with various financial institutions located primarily in Germany and Switzerland. The Company’s other revolving lines of credit, both secured and unsecured, are typically due upon demand with interest payable monthly.
	In January 2012, the Company entered into a note purchase agreement, referred to as the Note Purchase Agreement, with a group of accredited institutional investors. Pursuant to the Note Purchase Agreement, the Company issued and sold $240.0 million of senior notes, referred to as the Senior Notes, which consist of the following:
		·		$20 million 3.16% Series 2012A Senior Notes, Tranche A, due January 18, 2017;
		·		$15 million 3.74% Series 2012A Senior Notes, Tranche B, due January 18, 2019;
		·		$105 million 4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022; and
		·		$100 million 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024.
	Under the terms of the Note Purchase Agreement, the Company may issue and sell additional senior notes up to an aggregate principal amount of $600 million, subject to certain conditions. Interest on the Senior Notes is payable semi-annually on January 18 and July 18 of each year. The Senior Notes are unsecured obligations of the Company and are fully and unconditionally guaranteed by certain of the Company’s direct and indirect subsidiaries. The Senior Notes rank pari passu in right of repayment with the Company’s other senior unsecured indebtedness. The Company may prepay some or all of the Senior Notes at any time in an amount not less than 10% of the original aggregate principal amount of the Senior Notes to be prepaid, at a price equal to the sum of (a) 100% of the principal amount thereof, plus accrued and unpaid interest, and (b) the applicable make-whole amount, upon not less than 30 and no more than 60 days written notice to the holders of the Senior Notes. In the event of a change in control of the Company, as defined in the Note Purchase Agreement, the Company may be required to prepay the Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest.
	The Note Purchase Agreement contains affirmative covenants, including, without limitation, maintenance of corporate existence, compliance with laws, maintenance of insurance and properties, payment of taxes, addition of subsidiary guarantors and furnishing notices and other information. The Note Purchase Agreement also contains certain restrictive covenants that restrict the Company’s ability to, among other things, incur liens, transfer or sell assets, engage in certain mergers and consolidations and enter into transactions with affiliates. The Note Purchase Agreement also includes customary representations and warranties and events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding Senior Notes will become due and payable immediately without further action or notice. In the case of payment events of default, any holder of Senior Notes affected thereby may declare all Senior Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the Senior Notes may declare all the Senior Notes to be due and payable immediately. Pursuant to the Note Purchase Agreement, so long as any Senior Notes are outstanding the Company will not permit (i) its leverage ratio, as determined pursuant to the Note Purchase Agreement, as of the end of any fiscal quarter to exceed 3.50 to 1.00, (ii) its interest coverage ratio as determined pursuant to the Note Purchase Agreement as of the end of any fiscal quarter for any period of four consecutive fiscal quarters to be less than 2.50 to 1 or (iii) priority debt at any time to exceed 25% of consolidated net worth, as determined pursuant to the Note Purchase Agreement.
	As of September 30, 2014, the Company was in compliance with the covenants of the Note Purchase Agreement.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities	'
Derivative Instruments and Hedging Activities	'
	8.Derivative Instruments and Hedging Activities
	Interest Rate Risks
	The Company’s exposure to interest rate risk relates primarily to outstanding variable rate debt and adverse movements in the related short-term market rates. The most significant component of the Company’s interest rate risk relates to amounts outstanding under the Amended Credit Agreement, which totaled $112.5 million at September 30, 2014. The Company currently has a higher level of fixed rate debt, which limits the exposure to adverse movements in interest rates.
	Foreign Exchange Rate Risk Management
	The Company generates a substantial portion of its revenues and expenses in international markets, principally Germany and other countries in the European Union, Switzerland and Japan, which subjects its operations to the exposure of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company periodically enters into foreign currency contracts in order to minimize the volatility that fluctuations in exchange rates have on its monetary transactions. Under these arrangements, the Company typically agrees to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. Dollars or other currencies on specified dates with maturities of less than twelve months. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in the consolidated statements of income and comprehensive income. The Company had the following notional amounts outstanding under foreign currency contracts as of September 30, 2014 and December 31, 2013 (in millions):
	Buy	Notional		Sell		Maturity		Notional			Fair Value of			Fair Value of
		Amount in Buy						Amount in U.S.			Assets			Liabilities
		Currency						Dollars
	September 30, 2014:
	Euro	42.4		U.S. Dollars		October 2014		$	57.6		$	—		$	4.0
	Yen	9.6		Euro		October 2014		0.1			—			—
	Swiss Francs	44.4		U.S. Dollars		October 2014		49.8			—			3.2
								$	107.5		$	—		$	7.2
	December 31, 2013:
	Euro	40.4		U.S. Dollars		January 2014 to March 2014		$	54.5		$	1.1		$	—
	Swiss Francs	37.9		U.S. Dollars		January 2014		41.4			1.2			—
								$	95.9		$	2.3		$	—
	In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The contracts denominated in currencies other than the functional currency of the transacting parties amounted to $29.7 million for the delivery of products and $9.7 million for the purchase of products at September 30, 2014 and $21.7 million for the delivery of products and $9.5 million for the purchase of products at December 31, 2013. The changes in the fair value of these embedded derivatives are recorded as foreign currency exchange gains/losses in Interest and Other Income (Expense), net in the condensed consolidated statements of income and comprehensive income.
	Commodity Price Risk Management
	The Company has an arrangement with a customer under which it has a firm commitment to deliver copper based superconductors at a fixed price. In order to minimize the volatility that fluctuations in the price of copper have on the Company’s sales of these superconductors, the Company enters into commodity hedge contracts. At September 30, 2014 and December 31, 2013, the Company had fixed price commodity contracts with notional amounts aggregating $3.6 million and $3.4 million, respectively. The changes in the fair value of these commodity contracts are recorded in Interest and Other Income (Expense), net in the condensed consolidated statements of income and comprehensive income.
	The fair value of the derivative instruments described above is recorded in the consolidated balance sheets for the periods as follows (in millions):
				September 30,			December 31,
		Balance Sheet Location		2014			2013
	Derivative assets:
	Foreign exchange contracts	Other current assets		$	—		$	2.3
	Embedded derivatives in purchase and delivery contracts	Other current assets		0.3			0.2
	Fixed price commodity contracts	Other current assets		—			0.1
	Derivative liabilities:
	Foreign exchange contracts	Other current liabilities		$	7.2		$	—
	Embedded derivatives in purchase and delivery contracts	Other current liabilities			0.3			0.4
	Fixed price commodity contracts	Other current liabilities		0.1			—
	The impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments not designated as hedging instruments are as follows (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Foreign exchange contracts	$	(6.3	)	$	5.7		$	(9.5	)	$	2.9
	Embedded derivatives	0.2			(0.4		)	0.2			(0.2		)
	Fixed price commodity contracts	(0.2		)	0.5			(0.2		)	0.3
	Income (expense), net	$	(6.3	)	$	5.8		$	(9.5	)	$	3
	The amounts related to derivative instruments not designated as hedging instruments are recorded in Interest and Other Income (Expense), net in the condensed consolidated statements of income and comprehensive income.

Provision_for_Income_Taxes

Provision for Income Taxes	9 Months Ended
	Sep. 30, 2014
Provision for Income Taxes	'
Provision for Income Taxes	'
	9.Provision for Income Taxes
	The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. In addition, the Company accounts for uncertain tax positions that have reached a minimum recognition threshold.
	The income tax provision for the three months ended September 30, 2014 and 2013 was $2.7 million and $9.9 million, respectively, representing effective tax rates of 30.0% and 36.9%, respectively.  The income tax provision for the nine months ended September 30, 2014 and 2013 was $24.7 million and $24.9 million respectively, representing effective tax rates of 42.7% and 35.2%, respectively.  The Company’s effective tax rate for the three and nine months ended September 30, 2014 differed from the statutory rate primarily due to unbenefited domestic losses. The Company’s effective tax rate may change over time as the amount or mix of income and taxes changes amongst the jurisdictions in which the Company is subject to tax.
	As of September 30, 2014 and December 31, 2013, the Company has unrecognized tax benefits, excluding penalties and interest, of approximately $31.7 million and $32.7 million, respectively, of which $13.8 million and $14.1 million, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of September 30, 2014 and December 31, 2013, approximately $3.9 million and $3.8 million, respectively, of accrued interest and penalties related to uncertain tax positions was included in other long-term liabilities on the unaudited condensed consolidated balance sheets. Penalties and interest related to unrecognized tax benefits of $0.2 million were recorded in the provision for income taxes during the three and nine months ended September 30, 2014. Penalties and interest related to unrecognized tax benefits of $0.3 million and $(0.1) million were recorded during the three and nine months ended September 30, 2013, respectively.
	The Company files tax returns in the United States, which include federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States and Switzerland to be its significant tax jurisdictions.  The tax years 2009 to 2013 are open tax years in these significant jurisdictions. During the three months ended March 31, 2014, the Company settled a tax audit in the United States for the tax year 2010.  The amount of the settlement was immaterial to the condensed consolidated financial statements.  Tax years 2011 to 2013 remain open for examination in the United States.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies	'
Commitments and Contingencies	'
	10.Commitments and Contingencies
	Legal
	Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. The Company believes the outcome of these proceedings, individually and in the aggregate, will not have a material impact on the Company’s financial position or results of operations. As of September 30, 2014 and December 31, 2013, accruals recorded for such potential contingencies were immaterial to the condensed consolidated financial statements.
	Internal Investigation and Compliance Matters
	As previously reported, the Audit Committee of the Company’s Board of Directors, assisted by independent outside counsel and an independent forensic consulting firm, conducted an internal investigation in response to anonymous communications received by the Company alleging improper conduct in connection with the China operations of the Company’s Bruker Optics subsidiary. The Audit Committee’s investigation, which began in 2011 and was completed in the first quarter of 2012, included a review of compliance by Bruker Optics and its employees in China and Hong Kong with the requirements of the Foreign Corrupt Practices Act (“FCPA”) and other applicable laws and regulations.
	Also as previously reported, the investigation found evidence indicating that payments were made that improperly benefited employees or agents of government-owned enterprises in China and Hong Kong. The investigation also found evidence that certain employees of Bruker Optics in China and Hong Kong failed to comply with the Company’s policies and standards of conduct. As a result, the Company took personnel actions, including the termination of certain individuals. The Company also terminated its business relationships with certain third party agents, implemented an enhanced FCPA compliance program, and strengthened the financial controls and oversight at its subsidiaries operating in China and Hong Kong. During 2011, the Company also initiated a review of the China operations of its other subsidiaries, with the assistance of an independent audit firm. On the basis of this review, the Company identified additional employees in Bruker subsidiaries operating in China who failed to comply with the Company’s policies and standards of conduct, and took additional personnel actions at certain of its subsidiaries.
	In August 2011, the Company voluntarily contacted the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) to advise both agencies of the internal investigation by the Audit Committee regarding the China operations of the Company’s Bruker Optics subsidiary.  In October 2011, the Company reported the existence of the internal investigation to the Hong Kong Joint Financial Intelligence Unit and Independent Commission Against Corruption (“ICAC”).  The Company has cooperated with the United States federal agencies and Hong Kong government authorities with respect to their inquiries and has provided documents and/or made witnesses available in response to requests from the governmental authorities reviewing this matter. The FCPA and related statutes and regulations provide for potential monetary penalties as well as criminal and civil sanctions in connection with FCPA violations.
	The Company has been advised that the ICAC has completed its review and does not plan to take any action against the Company. The Company is engaged in discussions with Staff of the SEC to resolve the matters under investigation. During the three months ended September 30, 2014, the Company accrued $2.4 million recorded within Interest and Other Income (Expense), net in the accompanying condensed consolidated statements of income and comprehensive income representing the Company’s best estimate of probable loss associated with this matter. The Company will continue to evaluate the accrual pending final resolution of the investigation and the related discussions with the SEC and DOJ.
	Letters of Credit and Guarantees
	At September 30, 2014 and December 31, 2013, the Company had bank guarantees of $145.7 million and $171.2 million, respectively, for its customer advances. These arrangements guarantee the refund of advance payments received from customers in the event that the merchandise is not delivered or warranty obligations are not fulfilled in compliance with the terms of the contract. These guarantees affect the availability of the Company’s lines of credit.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income	'
Accumulated Other Comprehensive Income	'
	11.Accumulated Other Comprehensive Income (Loss)
	Comprehensive income (loss) refers to revenues, expenses, gains and losses that under U.S. GAAP are included in other comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity, net of tax. The Company’s other comprehensive income (loss) is composed primarily of foreign currency translation adjustments and changes in the funded status of defined benefit pension plans. The following is a summary of comprehensive income (loss) (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Consolidated net income	$	6.3		$	16.9		$	33.1		$	45.9
	Foreign currency translation adjustments	(84.1		)	37.6			(84.7		)	12.3
	Pension liability adjustments	1.1			(1.0		)	1			0.7
	Other	—			—			0.3			—
	Net comprehensive income (loss)	(76.7		)	53.5			(50.3		)	58.9
	Less: Comprehensive income (loss) attributable to noncontrolling interests	0.8			0.3			2.5			1
	Comprehensive income (loss) attributable to Bruker Corporation	$	(77.5	)	$	53.2		$	(52.8	)	$	57.9
	The following is a summary of the components of accumulated other comprehensive income (loss), net of tax, at September 30, 2014 (in millions):
		Foreign			Pension			Accumulated
		Currency			Liability			Other
		Translation			Adjustment			Comprehensive
								Income
	Balance at December 31, 2013	$	197.6		$	(15.2	)	$	182.4
	Other comprehensive income (loss) before reclassifications	(84.7		)	1			(83.7		)
	Balance at September 30, 2014	$	112.9		$	(14.2	)	$	98.7

Noncontrolling_Interests

Noncontrolling Interests	9 Months Ended
	Sep. 30, 2014
Noncontrolling Interests	'
Noncontrolling Interests	'
	12.Noncontrolling Interests
	Noncontrolling interests represent the minority shareholders’ proportionate share of the Company’s majority owned subsidiaries. The following table sets forth the changes in noncontrolling interests (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Balance at beginning of period	$	5.1		$	3.8		$	4.1		$	3.1
	Net income	0.8			0.3			2.5			1
	Cash payments to noncontrolling interests	—			(0.6		)	(1.1		)	(0.6		)
	Other	(0.3		)	—			0.1			—
	Balance at end of period	$	5.6		$	3.5		$	5.6		$	3.5

Other_Charges

Other Charges	9 Months Ended
	Sep. 30, 2014
Other Charges	'
Other Charges	'
	13.Other Charges
	The components of Other Charges were as follows (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Professional fees incurred in connection with internal investigation	$	0.3		$	0.7		$	3.1		$	5.3
	Acquisition-related charges	1.2			1.1			2.1			1.6
	Information technology transformation costs	1.1			—			2.4			—
	Restructuring charges	2.8			8.6			7.0			13.6
	Long-lived asset impairments	6.9			—			6.9			—
	Factory relocation costs	—			0.1			—			0.6
	Other charges	$	12.3		$	10.5		$	21.5		$	21.1
	Beginning in the fourth quarter of 2012 and continuing in 2013 and 2014, the Company commenced productivity improvement initiatives at both BSI and BEST in an effort to better optimize its operations.  These restructuring initiatives include the divestiture of certain non-core businesses, outsourcing of various manufacturing activities, transferring or ceasing operations at certain facilities and an overall right-sizing within the Company based on the then current business environments.
	The Company recorded total restructuring charges during the three and nine months ended September 30, 2014 of $16.2 million and $29.3 million, respectively, related to these initiatives, all within BSI.  For the three months ended September 30, 2014, the charges consisted of $10.1 million of inventory provisions for excess inventory, $4.1 million of severance costs and $2.0 million of exit related costs, such as professional service and facility exit charges. For the nine months ended September 30, 2014, the charges consisted of $12.1 million of inventory provisions for excess inventory, $11.3 million of severance costs and $5.9 million of exit related costs. During the three and nine months ended September 30, 2014, the Company has recorded restructuring charges of $13.4 million and $22.3 million, respectively, as a component of Cost of Revenue and $2.8 million and $7.0 million, respectively, as a component of Other Charges in the accompanying condensed consolidated statement of income and comprehensive income.
	In July 2014, the Company’s Board of Directors approved a plan (the Plan) to divest certain assets and implement a restructuring program in the CAM division within the Bruker CALID Group. The Plan was developed as a result of management’s conclusion that the CAM business would be unable to achieve acceptable financial performance in the next two years. Divestment and restructuring actions in connection with the Plan are expected to result in a reduction of CAM’s employee headcount by approximately 200 people. Restructuring and other one-time charges in connection with the Plan through the first half of 2015, including costs recorded in the third of quarter of 2014, are expected to be between $25 and $30 million, of which $8 to $11 million relate to employee separation and facility exit costs, and $17 to $19 million are estimated for inventory write-downs and asset impairments. The current expected restructuring and other one-time charges in connection with the Plan are lower than previously announced due to divestiture activity noted below.
	Included in the total restructuring charges discussed above are restructuring expenses recorded during the third quarter of 2014 specifically related to the Plan of $13.1 million, consisting of $10.1 million for inventory write-downs and $3.0 million of severance and exit costs, of which $11.1 was recorded as a component of Cost of Revenue and $2.0 million as a component of Other Charges, net in the accompanying condensed consolidated statement of income and comprehensive income.  The Company determined the approval of the Plan was an indicator requiring the evaluation of the long-lived assets, which included property, plant and equipment and definite-lived intangible assets, within the CAM division for recoverability. The Company performed a valuation during the three months ended September 30, 2014 and determined that certain long-lived assets were impaired. The Company recorded an impairment charge of $6.9 million in the three and nine months ended September 30, 2014, consisting of $5.5 million of property, plant and equipment, and $1.4 million of definite-lived intangible assts. This impairment charge is included as a component of Other Charges in the accompanying condensed consolidated statement of income and comprehensive income.
	In addition, in September 2014 the Company divested the assets of the CAM division’s Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) product line.  The gain on sale of the product line of $8.7 million has been recorded as part of Interest and Other Income (Expense), net within the accompanying condensed consolidated statement of income and comprehensive income.
	Please see Note 17 — Subsequent Events, for information regarding activity subsequent to September 30, 2014 related to the Plan.
	The following table sets forth the changes in the restructuring reserves for the nine months ended September 30, 2014 (in millions):
		Total			Provisions			Severance			Exit Costs
					for Excess
					Inventory
	Balance at December 31, 2013	$	11.5		$	2		$	8.4		$	1.1
	Restructuring charges	29.3			12.1			11.3			5.9
	Cash payments	(16.1		)	(0.1		)	(10.0		)	(6.0		)
	Non-cash adjustments	(3.9		)	(2.2		)	(1.4		)	(0.3		)
	Foreign currency effect	(0.8		)	(0.1		)	(0.6		)	(0.1		)
	Balance at September 30, 2014	$	20		11.7			$	7.7		$	0.6

Interest_and_Other_Income_Expe

Interest and Other Income (Expense), Net	9 Months Ended
	Sep. 30, 2014
Interest and Other Income (Expense), Net	'
Interest and Other Income (Expense), Net	'
	14.Interest and Other Income (Expense), Net
	The components of interest and other income (expense), net, were as follows (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Interest expense, net	$	(3.2	)	$	(3.2	)	$	(9.3	)	$	(9.4	)
	Exchange gains (losses) on foreign currency transactions	0.5			(1.7		)	(1.1		)	(6.8		)
	Gain on disposal of product line	8.7			—			9			0.9
	Other	(1.9		)	0.2			(1.7		)	(1.1		)
	Interest and other income (expense), net	$	4.1		$	(4.7	)	$	(3.1	)	$	(16.4	)

Business_Segment_Information

Business Segment Information	9 Months Ended
	Sep. 30, 2014
Business Segment Information	'
Business Segment Information	'
	15.Business Segment Information
	The Company has two reporting segments, BSI and BEST, as discussed in Footnote 1 to the condensed consolidated financial statements.
	Revenue and operating income by reporting segment are presented below (in millions):
			Three Months Ended September 30,						Nine Months Ended September 30,
			2014			2013			2014			2013
	Revenue:
	BSI		$	383.4		$	410.6		$	1,198.80		$	1,198.50
	BEST		40			32.5			116.2			100.8
	Eliminations (a)		(3.6		)	(4.1		)	(14.1		)	(12.0		)
	Total revenue		$	419.8		$	439		$	1,300.90		$	1,287.30
	Operating Income (Loss):
	BSI		$	0.8		$	33.8		$	48.5		$	84
	BEST		3.9			(0.8		)	11.1			6.7
	Corporate, eliminations and other (b)		0.2			(1.5		)	1.3			(3.5		)
	Total operating income		$	4.9		$	31.5		$	60.9		$	87.2
		(a)		Represents product and service revenue between reportable segments.
		(b)		Represents corporate costs and eliminations not allocated to the reportable segments.
	Total assets by reporting segment are as follows (in millions):
			September 30,			December 31,
			2014			2013
	Assets:
	BSI		$	1,864.90		$	1,925.30
	BEST		107.1			146.5
	Eliminations and other (a)		(61.4		)	(83.5		)
	Total assets		$	1,910.60		$	1,988.30
		(a)		Assets not allocated to the reportable segments and eliminations of intercompany transactions.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
Recent Accounting Pronouncements	'
Recent Accounting Pronouncements	'
	16.Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes the revenue recognition requirements under ASC Topic 605. The new guidance was the result of a joint project between the FASB and the International Accounting Standards Board to clarify the principles for recognizing revenue and to develop common revenue standards for GAAP and International Financial Reporting Standards. The core principle of the new guidance is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU No. 2014-09 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods within those years. Early application is not permitted. The Company is currently assessing the impact of adoption of the new guidance may have on its consolidated financial statements.
	In April 2014, the FASB issued ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, an amendment to ASC Topic 205.  Under the amendment, a disposal of a component of an entity or a group of components of an entity are required to be reported in discontinued operations if the disposal represents a strategic shift that has, or will have, a major effect on an entity’s operations and financial results.  The amendment also requires additional disclosures about discontinued operations as well as individually significant components of an entity that do not qualify for discontinued operations presentation in the financial statements. ASU No. 2014-08 is effective on a prospective basis for fiscal years beginning after December 15, 2014 and interim periods within annual periods beginning on or after December 15, 2015, with early adoption permitted.  The Company adopted this amendment in the second quarter of 2014 and has incorporated the guidance within its financial statements and related footnote disclosures. The adoption did not have a material impact on its condensed consolidated financial statements for the three or nine months ended September 30, 2014.
	In July 2013, the FASB issued ASU No. 2013-11, Income Taxes, an amendment to ASC Topic 740 related to the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists. Under this amendment, an unrecognized tax benefit is to be presented as a decrease in a deferred tax asset where a net operating loss, a similar tax loss, or a tax credit carryforward exists and certain criteria are met. ASU No. 2013-11 is effective for fiscal years beginning after December 15, 2013.  The Company adopted this amendment in the first quarter of 2014.  The adoption did not have a material impact on its condensed consolidated financial statements for the three or nine months ended September 30, 2014.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events	'
Subsequent Events	'
	17.Subsequent Events
	In October 2014, as part of the Plan discussed in Note 13. Other Charges, net above, the Company divested certain assets of the Gas Chromatography and Gas Chromatography Single Quadrupole mass spectrometry products of the CAM division. The sale will be accounted for in the fourth quarter of 2014. The total assets sold and resulting gain (loss) on sale is not material to the condensed consolidated financial statements.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Stock-Based Compensation	'
Stock-based compensation expense	'
	The Company recorded stock-based compensation expense as follows (in millions):
			Three Months Ended September 30,						Nine Months Ended September 30,
			2014			2013			2014			2013
	Stock options		$	1.7		$	1.3		$	4.7		$	3.9
	Restricted stock		0.4			0.3			2.4			0.9
	Total stock-based compensation		$	2.1		$	1.6		$	7.1		$	4.8
Assumptions regarding volatility, expected term, dividend yield and risk-free interest rates	'
	Assumptions regarding volatility, expected life, dividend yield and risk-free interest rates are required for the Black-Scholes model and are presented in the table below:
			2014		2013
	Risk-free interest rates		1.81%-2.10%		1.07%-2.45%
	Expected life		6.0-6.25 years		6.5 years
	Volatility		53.24%-56.24%		54.9%
	Expected dividend yield		0.0%		0.0%
Schedule of stock option activity	'
	Stock option activity for the nine months ended September 30, 2014 was as follows:
			Shares		Weighted			Weighted		Aggregate
			Subject to		Average			Average		Intrinsic Value
			Options		Option Price			Remaining		(in millions) (b)
								Contractual
								Term (Yrs)
	Outstanding at December 31, 2013		4,877,564		$	13.12
	Granted		990,670		20.7
	Exercised		(807,275	)	9.47
	Forfeited		(181,220	)	19.29
	Outstanding at September 30, 2014		4,879,739		$	15.2		6.7		$	19.5
	Exercisable at September 30, 2014		2,496,016		$	12.23		4.9		$	16
	Exercisable and expected to vest at September 30, 2014 (a)		4,758,169		$	15.12		6.6		$	19.3
		(a)		In addition to the options that are vested at September 30, 2014, the Company expects a portion of the unvested options to vest in the future. Options expected to vest in the future are determined by applying an estimated forfeiture rate to the options that are unvested as of September 30, 2014.
		(b)		The aggregate intrinsic value is based on the positive difference between the fair value of the Company’s common stock price of $18.52 on September 30, 2014, or the date of exercises, as appropriate, and the exercise price of the underlying stock options.
Schedule of restricted stock activity	'
	Restricted stock activity for the nine months ended September 30, 2014 was as follows:
			Shares		Weighted
			Subject to		Average Grant
			Restriction		Date Fair
					Value
	Outstanding at December 31, 2013		357,948		$	16.65
	Granted		112,129		20.68
	Vested		(160,352	)	18.41
	Outstanding at September 30, 2014		309,725		$	17.2

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share	'
Summary of the computation of basic and diluted average shares outstanding and net income per common share	'
	The following table sets forth the computation of basic and diluted average shares outstanding (in millions, except per share amounts):
		Three Months Ended Sept 30,				Nine Months Ended Sept 30,
		2014		2013		2014		2013
	Net income attributable to Bruker Corporation, as reported	$	5.5	$	16.6	$	30.6	$	44.9
	Weighted average shares outstanding:
	Weighted average shares outstanding-basic	168.0		167.0		167.5		166.6
	Effect of dilutive securities:
	Stock options and restricted stock	1.6		1.7		2.0		1.8
		169.6		168.7		169.5		168.4
	Net income per common share attributable to Bruker Corporation shareholders:
	Basic and diluted	$	0.03	$	0.10	$	0.18	$	0.27

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value of Financial Instruments	'
Schedule of financial instruments measured at fair value on a recurring basis	'
	The following tables set forth the Company’s financial instruments that are measured at fair value on a recurring basis and presents them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement at September 30, 2014 and December 31, 2013 (in millions):
	September 30, 2014	Total			Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets		Observable		Inputs
					Available		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets:
	Cash equivalents	$	114.8		$	114.8	$	—	$	—
	Short-term investments	113.1			113.1		—		—
	Restricted cash	1.8			1.8		—		—
	Embedded derivatives in purchase and delivery contracts	0.3			—		0.3		—
	Long-term restricted cash	3.8			3.8		—		—
	Total assets recorded at fair value	$	233.8		$	233.5	$	0.3	$	—
	Liabilities:
	Contingent consideration	$	15.8		$	—	$	—	$	15.8
	Foreign exchange contracts	7.2			—		7.2		—
	Embedded derivatives in purchase and delivery contracts	0.3			—		0.3		—
	Fixed price commodity contracts	0.1			—		0.1		—
	Total liabilities recorded at fair value	$	23.4		$	—	$	7.6	$	15.8
	December 31, 2013	Total			Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets		Observable		Inputs
					Available		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets:
	Cash equivalents	$	6.8		$	6.8	$	—	$	—
	Restricted cash	2.7			2.7		—		—
	Foreign exchange contracts	2.3			—		2.3		—
	Embedded derivatives in purchase and delivery contracts	0.2			—		0.2		—
	Fixed price commodity contracts	0.1			—		0.1		—
	Long-term restricted cash	4.0			4.0		—		—
	Total assets recorded at fair value	$	16.1		$	13.5	$	2.6	$	—
	Liabilities:
	Contingent consideration	$	7.0		$	—	$	—	$	7.0
	Embedded derivatives in purchase and delivery contracts	0.4			—		0.4		—
	Total liabilities recorded at fair value	$	7.4		$	—	$	0.4	$	7.0
Schedule of changes in contingent consideration liabilities	'
	The following table sets forth the changes in contingent consideration liabilities for the nine months ended September 30, 2014 (in millions):
	Balance at December 31, 2013	$	7
	Current period additions	9.2
	Current period adjustments	0.1
	Current period settlements	(0.5		)
	Balance at September 30, 2014	$	15.8

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventories	'
Schedule of inventories	'
	Inventories consisted of the following (in millions):
		September 30,		December 31,
		2014		2013
	Raw materials	$	172.5	$	189.7
	Work-in-process	199.2		196.5
	Finished goods	149.2		155.3
	Demonstration units	45.9		48.3
	Inventories	$	566.8	$	589.8

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Other Intangible Assets	'
Schedule of changes in the carrying amount of goodwill	'
	The following table sets forth the changes in the carrying amount of goodwill for the nine months ended September 30, 2014 (in millions):
	Balance at December 31, 2013	$	127.4
	Current period additions	11
	Current period adjustments	(0.1		)
	Foreign currency effect	(3.2		)
	Balance at September 30, 2014	$	135.1
Summary of intangible assets	'
	The following is a summary of intangible assets (in millions):
		September 30, 2014								December 31, 2013
		Gross			Accumulated			Net Carrying		Gross		Accumulated			Net Carrying
		Carrying			Amortization			Amount		Carrying		Amortization			Amount
		Amount								Amount
	Existing technology and related patents	$	151.2		$	(76.7	)	$	74.5	$	157.9	$	(68.2	)	$	89.7
	Customer relationships	13.7			(5.3		)	8.4		18		(7.8		)	10.2
	Trade names	0.1			(0.1		)	—		0.2		(0.2		)	—
	Intangible assets subject to amortization	165			(82.1		)	82.9		176.1		(76.2		)	99.9
	In-process research and development	5.7			—			5.7		5.7		—			5.7
	Intangible assets	$	170.7		$	(82.1	)	$	88.6	$	181.8	$	(76.2	)	$	105.6

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt	'
Components of debt obligations	'
	The Company’s debt obligations as of September 30, 2014 and December 31, 2013 consisted of the following (in millions):
		September 30,			December 31,
		2014			2013
	US Dollar revolving loan under the Amended Credit Agreement	$	112.5		$	112.5
	US Dollar notes under the Note Purchase Agreement	240			240
	Capital lease obligations and other loans	2.7			2.5
	Total debt	355.2			355
	Current portion of long-term debt	(0.7		)	(0.7		)
	Total long-term debt, less current portion	$	354.5		$	354.3
Summary of maximum commitments and net amounts available under revolving loans and lines of credit	'
	The following is a summary of the maximum commitments and net amounts available to the Company under revolving loans and lines of credit as of September 30, 2014 (in millions):
		Weighted		Total Amount			Outstanding		Outstanding		Total Amount
		Average		Committed by			Borrowings		Letters of		Available
		Interest Rate		Lenders					Credit
	Amended Credit Agreement	1.3	%	$	250.0		$	112.5	$	7.4	$	130.1
	Other revolving loans	—		260.3			—		138.3		122.0
	Total revolving loans			$	510.3		$	112.5	$	145.7	$	252.1

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities	'
Schedule of notional amounts outstanding under foreign currency contracts	'
	The Company had the following notional amounts outstanding under foreign currency contracts as of September 30, 2014 and December 31, 2013 (in millions):
	Buy	Notional		Sell		Maturity		Notional			Fair Value of			Fair Value of
		Amount in Buy						Amount in U.S.			Assets			Liabilities
		Currency						Dollars
	September 30, 2014:
	Euro	42.4		U.S. Dollars		October 2014		$	57.6		$	—		$	4.0
	Yen	9.6		Euro		October 2014		0.1			—			—
	Swiss Francs	44.4		U.S. Dollars		October 2014		49.8			—			3.2
								$	107.5		$	—		$	7.2
	December 31, 2013:
	Euro	40.4		U.S. Dollars		January 2014 to March 2014		$	54.5		$	1.1		$	—
	Swiss Francs	37.9		U.S. Dollars		January 2014		41.4			1.2			—
								$	95.9		$	2.3		$	—
Schedule of fair value and balance sheet location of derivative instruments	'
	The fair value of the derivative instruments described above is recorded in the consolidated balance sheets for the periods as follows (in millions):
				September 30,			December 31,
		Balance Sheet Location		2014			2013
	Derivative assets:
	Foreign exchange contracts	Other current assets		$	—		$	2.3
	Embedded derivatives in purchase and delivery contracts	Other current assets		0.3			0.2
	Fixed price commodity contracts	Other current assets		—			0.1
	Derivative liabilities:
	Foreign exchange contracts	Other current liabilities		$	7.2		$	—
	Embedded derivatives in purchase and delivery contracts	Other current liabilities			0.3			0.4
	Fixed price commodity contracts	Other current liabilities		0.1			—
Schedule of impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments not designated as hedging instruments	'
	The impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments not designated as hedging instruments are as follows (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Foreign exchange contracts	$	(6.3	)	$	5.7		$	(9.5	)	$	2.9
	Embedded derivatives	0.2			(0.4		)	0.2			(0.2		)
	Fixed price commodity contracts	(0.2		)	0.5			(0.2		)	0.3
	Income (expense), net	$	(6.3	)	$	5.8		$	(9.5	)	$	3

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income	'
Summary of comprehensive income	'
	The following is a summary of comprehensive income (loss) (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Consolidated net income	$	6.3		$	16.9		$	33.1		$	45.9
	Foreign currency translation adjustments	(84.1		)	37.6			(84.7		)	12.3
	Pension liability adjustments	1.1			(1.0		)	1			0.7
	Other	—			—			0.3			—
	Net comprehensive income (loss)	(76.7		)	53.5			(50.3		)	58.9
	Less: Comprehensive income (loss) attributable to noncontrolling interests	0.8			0.3			2.5			1
	Comprehensive income (loss) attributable to Bruker Corporation	$	(77.5	)	$	53.2		$	(52.8	)	$	57.9
Summary of the components of accumulated other comprehensive income (loss), net of tax	'
	The following is a summary of the components of accumulated other comprehensive income (loss), net of tax, at September 30, 2014 (in millions):
		Foreign			Pension			Accumulated
		Currency			Liability			Other
		Translation			Adjustment			Comprehensive
								Income
	Balance at December 31, 2013	$	197.6		$	(15.2	)	$	182.4
	Other comprehensive income (loss) before reclassifications	(84.7		)	1			(83.7		)
	Balance at September 30, 2014	$	112.9		$	(14.2	)	$	98.7

Noncontrolling_Interests_Table

Noncontrolling Interests (Tables)	9 Months Ended
	Sep. 30, 2014
Noncontrolling Interests	'
Schedule of changes in noncontrolling interests	'
	The following table sets forth the changes in noncontrolling interests (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Balance at beginning of period	$	5.1		$	3.8		$	4.1		$	3.1
	Net income	0.8			0.3			2.5			1
	Cash payments to noncontrolling interests	—			(0.6		)	(1.1		)	(0.6		)
	Other	(0.3		)	—			0.1			—
	Balance at end of period	$	5.6		$	3.5		$	5.6		$	3.5

Other_Charges_Tables

Other Charges (Tables)	9 Months Ended
	Sep. 30, 2014
Other Charges	'
Components of Other Charges	'
	The components of Other Charges were as follows (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Professional fees incurred in connection with internal investigation	$	0.3		$	0.7		$	3.1		$	5.3
	Acquisition-related charges	1.2			1.1			2.1			1.6
	Information technology transformation costs	1.1			—			2.4			—
	Restructuring charges	2.8			8.6			7.0			13.6
	Long-lived asset impairments	6.9			—			6.9			—
	Factory relocation costs	—			0.1			—			0.6
	Other charges	$	12.3		$	10.5		$	21.5		$	21.1
Schedule of changes in the restructuring reserves	'
	The following table sets forth the changes in the restructuring reserves for the nine months ended September 30, 2014 (in millions):
		Total			Provisions			Severance			Exit Costs
					for Excess
					Inventory
	Balance at December 31, 2013	$	11.5		$	2		$	8.4		$	1.1
	Restructuring charges	29.3			12.1			11.3			5.9
	Cash payments	(16.1		)	(0.1		)	(10.0		)	(6.0		)
	Non-cash adjustments	(3.9		)	(2.2		)	(1.4		)	(0.3		)
	Foreign currency effect	(0.8		)	(0.1		)	(0.6		)	(0.1		)
	Balance at September 30, 2014	$	20		11.7			$	7.7		$	0.6

Interest_and_Other_Income_Expe1

Interest and Other Income (Expense), Net (Tables)	9 Months Ended
	Sep. 30, 2014
Interest and Other Income (Expense), Net	'
Components of interest and other income (expense), net	'
	The components of interest and other income (expense), net, were as follows (in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Interest expense, net	$	(3.2	)	$	(3.2	)	$	(9.3	)	$	(9.4	)
	Exchange gains (losses) on foreign currency transactions	0.5			(1.7		)	(1.1		)	(6.8		)
	Gain on disposal of product line	8.7			—			9			0.9
	Other	(1.9		)	0.2			(1.7		)	(1.1		)
	Interest and other income (expense), net	$	4.1		$	(4.7	)	$	(3.1	)	$	(16.4	)

Business_Segment_Information_T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2014
Business Segment Information	'
Schedule of reporting segment information	'
	Revenue and operating income by reporting segment are presented below (in millions):
			Three Months Ended September 30,						Nine Months Ended September 30,
			2014			2013			2014			2013
	Revenue:
	BSI		$	383.4		$	410.6		$	1,198.80		$	1,198.50
	BEST		40			32.5			116.2			100.8
	Eliminations (a)		(3.6		)	(4.1		)	(14.1		)	(12.0		)
	Total revenue		$	419.8		$	439		$	1,300.90		$	1,287.30
	Operating Income (Loss):
	BSI		$	0.8		$	33.8		$	48.5		$	84
	BEST		3.9			(0.8		)	11.1			6.7
	Corporate, eliminations and other (b)		0.2			(1.5		)	1.3			(3.5		)
	Total operating income		$	4.9		$	31.5		$	60.9		$	87.2
		(a)		Represents product and service revenue between reportable segments.
		(b)		Represents corporate costs and eliminations not allocated to the reportable segments.
	Total assets by reporting segment are as follows (in millions):
			September 30,			December 31,
			2014			2013
	Assets:
	BSI		$	1,864.90		$	1,925.30
	BEST		107.1			146.5
	Eliminations and other (a)		(61.4		)	(83.5		)
	Total assets		$	1,910.60		$	1,988.30
		(a)		Assets not allocated to the reportable segments and eliminations of intercompany transactions.

Description_of_Business_Detail

Description of Business (Details)	9 Months Ended
	Sep. 30, 2014
	segment
Description of Business	'
Number of reporting segments	2
BSI	'
Description of Business	'
Segment revenue (as a percent)	92.00%
Number of operating segments	3

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

In Millions, except Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

31-May-10

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Stock options

Stock options

Stock options

Stock options

Stock options

Stock options

Restricted stock

Restricted stock

Restricted stock

Restricted stock

Bruker Corporation Stock Plan

Bruker Corporation Stock Plan

Bruker Corporation Stock Plan

Bruker Corporation Stock Plan

Bruker Corporation Stock Plan

Minimum

Maximum

Minimum

Maximum

Stock options

Restricted stock

Stock-Based Compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total stock-based compensation

$2.10

$1.60

$7.10

$4.80

$1.70

$1.30

$4.70

$3.90

'

'

$0.40

$0.30

$2.40

$0.90

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'3 years

'5 years

'

'

'

'

'

'3 years

'5 years

'

'

Risk-free interest rate, minimum (as a percent)

'

'

'

'

'

'

1.81%

1.07%

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate, maximum (as a percent)

'

'

'

'

'

'

2.10%

2.45%

'

'

'

'

'

'

'

'

'

'

'

Expected life

'

'

'

'

'

'

'

'6 years 6 months

'6 years

'6 years 3 months

'

'

'

'

'

'

'

'

'

Volatility (as a percent)

'

'

'

'

'

'

'

54.90%

53.24%

56.24%

'

'

'

'

'

'

'

'

'

Expected dividend yield (as a percent)

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

Common stock authorized for issuance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

'

'

'

'

Stock option, Number of Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the beginning of the period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,877,564

'

Granted (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

990,670

'

Exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-807,275

'

Forfeited (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-181,220

'

Outstanding at the end of the period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,879,739

'

Exercisable at the end of the period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,496,016

'

Exercisable and expected to vest at the end of the period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,758,169

'

Stock options, Weighted Average Option Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the beginning of the period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$13.12

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20.70

'

Exercised (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$9.47

'

Forfeited (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19.29

'

Outstanding at the end of the period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.20

'

Exercisable at the end of the period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12.23

'

Exercisable and expected to vest at the end of the period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.12

'

Stock options, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the end of the period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years 8 months 12 days

'

Exercisable at the end of the period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years 10 months 24 days

'

Exercisable and expected to vest at the end of the period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years 7 months 6 days

'

Stock options, Aggregate Intrinsic Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the end of the period (in dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19.5

'

Exercisable at the end of the period (in dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16

'

Exercisable and expected to vest at the end of the period (in dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19.3

'

Fair value of the Company's common stock price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$18.52

'

Restricted stock, Number of Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the beginning of the period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

357,948

Granted (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

112,129

Vested (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-160,352

Outstanding at the end of the period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

309,725

Restricted stock, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the beginning of the period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16.65

Granted (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20.68

Vested (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$18.41

Outstanding at the end of the period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$17.20

Expected pre-tax stock-based compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20.80

$5

Weighted average remaining service period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 6 months

'3 years 2 months 12 days

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share	'	'	'	'
Net income attributable to Bruker Corporation, as reported	$5.50	$16.60	$30.60	$44.90
Weighted average shares outstanding:	'	'	'	'
Weighted average shares outstanding-basic	168	167	167.5	166.6
Effect of dilutive securities:	'	'	'	'
Stock options and restricted stock (in shares)	1.6	1.7	2	1.8
Weighted average shares outstanding-diluted	169.6	168.7	169.5	168.4
Net income per common share attributable to Bruker Corporation shareholders:	'	'	'	'
Basic and diluted (in dollars per share)	$0.03	$0.10	$0.18	$0.27
Stock options	'	'	'	'
Anti-dilutive securities	'	'	'	'
Number of shares excluded from the computation of diluted earnings per share	0.2	0.7	0.2	0.9

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Assets:	'	'
Short-term investments	$113.10	'
Significant Other Observable Inputs (Level 2)	'	'
Liabilities:	'	'
Long-term fixed interest rate debt	249.3	244.1
Recurring basis | Total	'	'
Assets:	'	'
Cash equivalents	114.8	6.8
Short-term investments	113.1	'
Restricted cash	1.8	2.7
Foreign exchange contracts	'	2.3
Embedded derivatives in purchase and delivery contracts	0.3	0.2
Fixed price commodity contracts	'	0.1
Long-term restricted cash	3.8	4
Total assets recorded at fair value	233.8	16.1
Liabilities:	'	'
Contingent consideration	15.8	7
Foreign exchange contracts	7.2	'
Embedded derivatives in purchase and delivery contracts	0.3	0.4
Fixed price commodity contracts	0.1	'
Total liabilities recorded at fair value	23.4	7.4
Recurring basis | Quoted Prices in Active Markets Available (Level 1)	'	'
Assets:	'	'
Cash equivalents	114.8	6.8
Short-term investments	113.1	'
Restricted cash	1.8	2.7
Long-term restricted cash	3.8	4
Total assets recorded at fair value	233.5	13.5
Recurring basis | Significant Other Observable Inputs (Level 2)	'	'
Assets:	'	'
Foreign exchange contracts	'	2.3
Embedded derivatives in purchase and delivery contracts	0.3	0.2
Fixed price commodity contracts	'	0.1
Total assets recorded at fair value	0.3	2.6
Liabilities:	'	'
Foreign exchange contracts	7.2	'
Embedded derivatives in purchase and delivery contracts	0.3	0.4
Fixed price commodity contracts	0.1	'
Total liabilities recorded at fair value	7.6	0.4
Recurring basis | Significant Unobservable Inputs (Level 3)	'	'
Liabilities:	'	'
Contingent consideration	15.8	7
Total liabilities recorded at fair value	$15.80	$7

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments (Details 2) (Contingent consideration, USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Contingent consideration	'
Fair value of financial instruments	'
Amount of changes to the fair value of the contingent consideration recognized in earnings	$0.10
Changes in contingent consideration liabilities	'
Balance at the beginning of the period	7
Current period additions	9.2
Current period adjustments	0.1
Current period settlements	-0.5
Balance at the end of the period	$15.80

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments (Details 3) (USD $)	3 Months Ended	9 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Minimum	Maximum
Investments in time and call deposits	'	'	'	'
Maturity of time deposits	'	'	'1 month	'6 months
Period of ability to redeem invested amounts on call deposits	'	'	'31 days	'95 days
Unrealized gains (losses) on available-for-sale securities	$0	$0	'	'

Inventories_Details

Inventories (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Inventories	'	'	'	'	'
Raw materials	$172.50	'	$172.50	'	$189.70
Work-in-process	199.2	'	199.2	'	196.5
Finished goods	149.2	'	149.2	'	155.3
Demonstration units	45.9	'	45.9	'	48.3
Inventories	566.8	'	566.8	'	589.8
Inventory-in-transit	78.8	'	78.8	'	81.9
Write-down of demonstration units	$7.40	$8	$22.60	$24	'

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Goodwill	'
Balance at the beginning of the period	$127.40
Current period additions	11
Current period adjustments	-0.1
Foreign currency effect	-3.2
Balance at the end of the period	$135.10

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Intangible assets:	'	'	'	'	'
Gross Carrying Amount, intangible assets subject to amortization	$165	'	$165	'	$176.10
Accumulated Amortization, intangible assets subject to amortization	-82.1	'	-82.1	'	-76.2
Net Carrying Amount, intangible assets subject to amortization	82.9	'	82.9	'	99.9
Gross Carrying Amount, total intangible assets	170.7	'	170.7	'	181.8
Net Carrying Amount, total intangible assets	88.6	'	88.6	'	105.6
Impairment charge on definite-lived intangible assets	1.4	'	1.4	'	'
Amortization expense related to intangible assets subject to amortization	5.1	5.1	15.1	15.3	'
CAM division	'	'	'	'	'
Intangible assets:	'	'	'	'	'
Impairment charge on definite-lived intangible assets	1.4	'	1.4	'	'
In-process research and development	'	'	'	'	'
Intangible assets:	'	'	'	'	'
Gross Carrying Amount, intangible assets not subject to amortization	5.7	'	5.7	'	5.7
Net Carrying Amount, total intangible assets	5.7	'	5.7	'	5.7
Existing technology and related patents	'	'	'	'	'
Intangible assets:	'	'	'	'	'
Gross Carrying Amount, intangible assets subject to amortization	151.2	'	151.2	'	157.9
Accumulated Amortization, intangible assets subject to amortization	-76.7	'	-76.7	'	-68.2
Net Carrying Amount, intangible assets subject to amortization	74.5	'	74.5	'	89.7
Customer relationships	'	'	'	'	'
Intangible assets:	'	'	'	'	'
Gross Carrying Amount, intangible assets subject to amortization	13.7	'	13.7	'	18
Accumulated Amortization, intangible assets subject to amortization	-5.3	'	-5.3	'	-7.8
Net Carrying Amount, intangible assets subject to amortization	8.4	'	8.4	'	10.2
Trade names	'	'	'	'	'
Intangible assets:	'	'	'	'	'
Gross Carrying Amount, intangible assets subject to amortization	0.1	'	0.1	'	0.2
Accumulated Amortization, intangible assets subject to amortization	($0.10)	'	($0.10)	'	($0.20)

Debt_Details

Debt (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	31-May-11
Debt	'	'	'
Total debt	$355.20	$355	'
Current portion of long-term debt	-0.7	-0.7	'
Total long-term debt, less current portion	354.5	354.3	'
Capital lease obligations and other loans	'	'	'
Debt	'	'	'
Total debt	2.7	2.5	'
US Dollar revolving loans under the Amended Credit Agreement	'	'	'
Debt	'	'	'
Total debt	112.5	112.5	'
Maximum commitment	250	'	250
Maximum leverage ratio	3	'	'
Minimum interest coverage ratio	3	'	'
US Dollar revolving loans under the Amended Credit Agreement | Minimum	'	'	'
Debt	'	'	'
Interest rate added to base rate (as a percent)	0.80%	'	'
Facility fee (as a percent)	0.20%	'	'
US Dollar revolving loans under the Amended Credit Agreement | Maximum	'	'	'
Debt	'	'	'
Interest rate added to base rate (as a percent)	1.65%	'	'
Facility fee (as a percent)	0.35%	'	'
US Dollar revolving loans under the Amended Credit Agreement | Prime rate	'	'	'
Debt	'	'	'
Variable interest rate base	'prime rate	'	'
US Dollar revolving loans under the Amended Credit Agreement | Federal Funds	'	'	'
Debt	'	'	'
Variable interest rate base	'federal funds rate	'	'
Interest rate added to base rate (as a percent)	0.50%	'	'
US Dollar revolving loans under the Amended Credit Agreement | Adjusted LIBOR	'	'	'
Debt	'	'	'
Variable interest rate base	'adjusted LIBOR	'	'
Interest rate added to base rate (as a percent)	1.00%	'	'
US Dollar revolving loans under the Amended Credit Agreement | LIBOR	'	'	'
Debt	'	'	'
Variable interest rate base	'LIBOR	'	'
US Dollar notes under the Note Purchase Agreement	'	'	'
Debt	'	'	'
Total debt	$240	$240	'

Debt_Details_2

Debt (Details 2) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	31-May-11	Sep. 30, 2014
In Millions, unless otherwise specified	Revolving Loans	Revolving Loans	US Dollar revolving loans under the Amended Credit Agreement	US Dollar revolving loans under the Amended Credit Agreement	Other revolving loans
Revolving loans	'	'	'	'	'
Weighted Average Interest Rate (as a percent)	'	'	1.30%	'	'
Total Amount Committed by Lenders	$510.30	'	$250	$250	$260.30
Outstanding Borrowings	112.5	'	112.5	'	'
Outstanding Letters of Credit	145.7	171.2	7.4	'	138.3
Total Amount Available	$252.10	'	$130.10	'	$122

Debt_Details_3

Debt (Details 3) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Jan. 31, 2012
US Dollar notes under the Note Purchase Agreement	'	'
Debt	'	'
Senior notes	'	$240
Additional aggregate principal amount that may be issued	600	'
Percentage of principal amount to be repaid in case of prepayment	100.00%	'
Percentage of principal amount to be repaid in case of prepayment and change in control	100.00%	'
Period for interest coverage ratio	'1 year	'
US Dollar notes under the Note Purchase Agreement | Minimum	'	'
Debt	'	'
Prepayment of notes as a percentage of original aggregate principal amount of the Notes to be prepaid	10.00%	'
Written notice period to holders of the Notes	'30 days	'
Consolidated interest coverage ratio	2.5	'
US Dollar notes under the Note Purchase Agreement | Maximum	'	'
Debt	'	'
Written notice period to holders of the Notes	'60 days	'
Priority debt as a percentage of consolidated net worth	25.00%	'
Consolidated leverage ratio	3.5	'
3.16% Series 2012A Senior Notes, Tranche A, due January 18, 2017	'	'
Debt	'	'
Senior notes	'	20
Interest rate, stated percentage	'	3.16%
3.74% Series 2012A Senior Notes, Tranche B, due January 18, 2019	'	'
Debt	'	'
Senior notes	'	15
Interest rate, stated percentage	'	3.74%
4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022	'	'
Debt	'	'
Senior notes	'	105
Interest rate, stated percentage	'	4.31%
4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024	'	'
Debt	'	'
Senior notes	'	$100
Interest rate, stated percentage	'	4.46%

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Activities (Details)

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

In Millions, unless otherwise specified

Foreign exchange contracts

Foreign exchange contracts

Embedded derivative in purchase and delivery contracts

Embedded derivative in purchase and delivery contracts

Embedded derivative in purchase and delivery contracts

Embedded derivative in purchase and delivery contracts

Embedded derivative in purchase and delivery contracts

Embedded derivative in purchase and delivery contracts

Fixed price commodity contracts

Fixed price commodity contracts

Fixed price commodity contracts

Fixed price commodity contracts

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

US Dollar revolving loans under the Amended Credit Agreement

Other current assets

Other current liabilities

USD ($)

USD ($)

Other current assets

Other current assets

Other current liabilities

Other current liabilities

USD ($)

USD ($)

Other current assets

Other current liabilities

USD ($)

USD ($)

USD ($)

USD ($)

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Embedded derivative in purchase and delivery contracts

Embedded derivative in purchase and delivery contracts

Embedded derivative in purchase and delivery contracts

Embedded derivative in purchase and delivery contracts

Fixed price commodity contracts

Fixed price commodity contracts

Fixed price commodity contracts

Fixed price commodity contracts

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

US Dollar:EUR

US Dollar:EUR

US Dollar:EUR

US Dollar:EUR

EUR:YEN

EUR:YEN

US Dollar:CHF

US Dollar:CHF

US Dollar:CHF

US Dollar:CHF

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Long

Long

USD ($)

Long

USD ($)

USD ($)

Long

Long

USD ($)

EUR (€)

USD ($)

EUR (€)

CHF

Derivative instruments and hedging activities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$112.50

Notional Amount

'

'

'

'

'

'

'

'

3.6

3.4

'

'

'

'

'

'

107.5

'

107.5

'

95.9

57.6

54.5

42.4

40.4

0.1

9.6

49.8

41.4

44.4

37.9

'

'

'

'

'

'

'

'

'

Fair Value of Assets

2.3

'

'

'

0.3

0.2

'

'

'

'

0.1

'

'

'

'

'

'

'

'

'

2.3

'

1.1

'

'

'

'

'

1.2

'

'

'

'

'

'

'

'

'

'

'

Fair Value of Liabilities

'

7.2

'

'

'

'

0.3

0.4

'

'

'

0.1

'

'

'

'

7.2

'

7.2

'

'

4

'

'

'

'

'

3.2

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount of derivative sale contracts

'

'

29.7

21.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount of derivative purchase contracts

'

'

9.7

9.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments

'

'

'

'

'

'

'

'

'

'

'

'

($6.30)

$5.80

($9.50)

$3

($6.30)

$5.70

($9.50)

$2.90

'

'

'

'

'

'

'

'

'

'

'

$0.20

($0.40)

$0.20

($0.20)

($0.20)

$0.50

($0.20)

$0.30

'

Provision_for_Income_Taxes_Det

Provision for Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Provision for Income Taxes	'	'	'	'	'
Income tax provision	$2.70	$9.90	$24.70	$24.90	'
Effective tax rates (as a percent)	30.00%	36.90%	42.70%	35.20%	'
Unrecognized tax benefits, excluding penalties and interest	31.7	'	31.7	'	32.7
Portion of unrecognized tax benefits, which if recognized, would result in a reduction of the effective tax rate	13.8	'	13.8	'	14.1
Accrued interest and penalties related to uncertain tax positions	3.9	'	3.9	'	3.8
Penalties and interest expense relating to unrecognized tax benefits	$0.20	$0.30	$0.20	($0.10)	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Revolving Loans	'	'
Commitments and contingencies	'	'
Bank guarantees primarily for customer advances	$145.70	$171.20
FCPA compliance in China and Hong Kong	'	'
Commitments and contingencies	'	'
Accruals for potential contingencies	$2.40	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Summary of comprehensive income	'	'	'	'
Consolidated net income	$6.30	$16.90	$33.10	$45.90
Foreign currency translation adjustments	-84.1	37.6	-84.7	12.3
Pension liability adjustments	1.1	-1	1	0.7
Other	'	'	0.3	'
Net comprehensive income (loss)	-76.7	53.5	-50.3	58.9
Less: Comprehensive income (loss) attributable to noncontrolling interests	0.8	0.3	2.5	1
Comprehensive income (loss) attributable to Bruker Corporation	($77.50)	$53.20	($52.80)	$57.90

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Details 2) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Balance at beginning of period	$182.40
Other comprehensive income (loss) before reclassifications	-83.7
Balance at end of period	98.7
Foreign Currency Translation	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Balance at beginning of period	197.6
Other comprehensive income (loss) before reclassifications	-84.7
Balance at end of period	112.9
Pension Liability Adjustment	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Balance at beginning of period	-15.2
Other comprehensive income (loss) before reclassifications	1
Balance at end of period	($14.20)

Noncontrolling_Interests_Detai

Noncontrolling Interests (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Noncontrolling interests	'	'	'	'
Balance at the beginning of period	$5.10	$3.80	$4.10	$3.10
Net income	0.8	0.3	2.5	1
Cash payments to noncontrolling interests	'	-0.6	-1.1	-0.6
Other	-0.3	'	0.1	'
Balance at the end of period	$5.60	$3.50	$5.60	$3.50

Other_Charges_Details

Other Charges (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Professional fees incurred in connection with internal investigation	$0.30	$0.70	$3.10	$5.30
Acquisition-related charges (income)	1.2	1.1	2.1	1.6
Information technology transformation costs	1.1	'	2.4	'
Restructuring charges	2.8	8.6	7	13.6
Long-lived asset impairments	6.9	'	6.9	'
Factory relocation costs	'	0.1	'	0.6
Other charges	12.3	10.5	21.5	21.1
Gain on disposal of product line	-8.7	'	-9	-0.9
Restructuring charges	'	'	'	'
Restructuring charges	'	'	29.3	'
Impairment charge	'	'	'	'
Impairment charge on definite-lived intangible assets	1.4	'	1.4	'
Cost of Revenue	'	'	'	'
Restructuring charges	'	'	'	'
Restructuring charges	13.4	'	22.3	'
Other Charges	'	'	'	'
Restructuring charges	'	'	'	'
Restructuring charges	2.8	'	7	'
Interest and other income expense	'	'	'	'
Gain on disposal of product line	'	'	-8.7	'
CAM division	'	'	'	'
Long-lived asset impairments	6.9	'	6.9	'
Period in which acceptable financial performance estimated to be unachievable	'	'	'2 years	'
Expected reduction of CAM's employee headcount	'	'	200	'
Restructuring charges	'	'	'	'
Restructuring charges	13.1	'	'	'
Charge to inventory provisions for excess inventory	10.1	'	'	'
Severance and exit costs	3	'	'	'
Impairment charge	'	'	'	'
Impairment charge on property, plant and equipment	'	'	5.5	'
Impairment charge on definite-lived intangible assets	1.4	'	1.4	'
CAM division | Minimum	'	'	'	'
Expected restructuring and related one-time charges	'	'	25	'
Restructuring and other one-time charges expected to result in future cash charges for employee separation and facility exit costs	'	'	8	'
Restructuring and other one-time charges estimated for inventory write down and assets impairments	'	'	17	'
CAM division | Maximum	'	'	'	'
Expected restructuring and related one-time charges	'	'	30	'
Restructuring and other one-time charges expected to result in future cash charges for employee separation and facility exit costs	'	'	11	'
Restructuring and other one-time charges estimated for inventory write down and assets impairments	'	'	19	'
CAM division | Cost of Revenue	'	'	'	'
Restructuring charges	'	'	'	'
Restructuring charges	11.1	'	'	'
CAM division | Other Charges	'	'	'	'
Restructuring charges	'	'	'	'
Restructuring charges	2	'	'	'
BSI	'	'	'	'
Restructuring charges	'	'	'	'
Restructuring charges	16.2	'	29.3	'
Charge to inventory provisions for excess inventory	10.1	'	12.1	'
Severance costs	4.1	'	11.3	'
Exit related costs	$2	'	$5.90	'

Other_Charges_Details_2

Other Charges (Details 2) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Changes in the restructuring reserves	'
Balance at the beginning of the period	$11.50
Restructuring charges	29.3
Cash payments	-16.1
Non-cash adjustments	-3.9
Foreign currency effect	-0.8
Balance at the end of the period	20
Provisions for Excess Inventory	'
Changes in the restructuring reserves	'
Balance at the beginning of the period	2
Restructuring charges	12.1
Cash payments	-0.1
Non-cash adjustments	-2.2
Foreign currency effect	-0.1
Balance at the end of the period	11.7
Severance	'
Changes in the restructuring reserves	'
Balance at the beginning of the period	8.4
Restructuring charges	11.3
Cash payments	-10
Non-cash adjustments	-1.4
Foreign currency effect	-0.6
Balance at the end of the period	7.7
Exit Costs	'
Changes in the restructuring reserves	'
Balance at the beginning of the period	1.1
Restructuring charges	5.9
Cash payments	-6
Non-cash adjustments	-0.3
Foreign currency effect	-0.1
Balance at the end of the period	$0.60

Interest_and_Other_Income_Expe2

Interest and Other Income (Expense), Net (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Interest and Other Income (Expense), Net	'	'	'	'
Interest expense, net	($3.20)	($3.20)	($9.30)	($9.40)
Exchange gains (losses) on foreign currency transactions	0.5	-1.7	-1.1	-6.8
Gain on disposal of product line	8.7	'	9	0.9
Other	-1.9	0.2	-1.7	-1.1
Interest and other income (expense), net	$4.10	($4.70)	($3.10)	($16.40)

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
			segment
Business Segment Information	'	'	'	'	'
Number of reporting segments	'	'	2	'	'
Revenue:	'	'	'	'	'
Total revenue	$419.80	$439	$1,300.90	$1,287.30	'
Operating Income:	'	'	'	'	'
Total operating income	4.9	31.5	60.9	87.2	'
Assets:	'	'	'	'	'
Total assets	1,910.60	'	1,910.60	'	1,988.30
Eliminations	'	'	'	'	'
Revenue:	'	'	'	'	'
Total revenue	-3.6	-4.1	-14.1	-12	'
Corporate, eliminations and other	'	'	'	'	'
Operating Income:	'	'	'	'	'
Total operating income	0.2	-1.5	1.3	-3.5	'
Assets:	'	'	'	'	'
Total assets	-61.4	'	-61.4	'	-83.5
BSI | Operating segments	'	'	'	'	'
Revenue:	'	'	'	'	'
Total revenue	383.4	410.6	1,198.80	1,198.50	'
Operating Income:	'	'	'	'	'
Total operating income	0.8	33.8	48.5	84	'
Assets:	'	'	'	'	'
Total assets	1,864.90	'	1,864.90	'	1,925.30
Energy and Supercon Technologies | Operating segments	'	'	'	'	'
Revenue:	'	'	'	'	'
Total revenue	40	32.5	116.2	100.8	'
Operating Income:	'	'	'	'	'
Total operating income	3.9	-0.8	11.1	6.7	'
Assets:	'	'	'	'	'
Total assets	$107.10	'	$107.10	'	$146.50